Absci said interim phase 1 data from its first-in-human trial of ABS-201 showed the antibody was well tolerated across all four blinded single-ascending-dose cohorts, with no serious adverse events reported through the June 8 data cutoff.
The study enrolled 32 healthy adults into doses of 150 mg, 450 mg, 900 mg and 1,800 mg given intravenously. Across those cohorts, all treatment-emergent adverse events were mild except for one moderate headache in cohort 3, which was judged unlikely to be related to treatment. Treatment-related adverse events were reported in five participants, and all were mild. Headache was the most common event, affecting four participants.
On the pharmacokinetic side, Absci said available interim data, including day 56 follow-up in the lower-dose cohorts, put ABS-201’s half-life at at least 65 days. That supports a dosing interval of two or three injections over a six-month period, pending further follow-up.
No apparent effect from anti-drug antibodies was seen in the interim blinded data.
The program has now moved into the subcutaneous multiple-ascending-dose stage in participants with androgenetic alopecia. Absci said it has initiated the first MAD cohort in that portion of the trial, which is evaluating 300 mg, 600 mg and 1,200 mg doses.
The company is targeting interim proof-of-concept data in the second half of 2026 and full proof-of-concept results in early 2027. The market has reacted to these announcements by moving the company's shares 19.64% to a price of $8.865. If you want to know more, read the company's complete 8-K report here.
